Moberg Pharma - Articles and news items

Moberg begins patient enrolment in US and Europe Phase 3 onychomycosis trials

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing…

Moberg Pharma announces plans to develop BUPI into Phase III

Industry news / 22 March 2016 / Victoria White

BUPI is a patent pending lozenge formulation of bupivacaine for pain management in oral mucositis in cancer patients…

Moberg announces positive data for BUPI in oral mucositis

Industry news / 11 January 2016 / Victoria White

Oral mucositis is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy…

onychomycosis nail

Moberg Pharma announces grant of EU Patent for MOB-015 related to topical treatment of onychomycosis

Industry news / 26 March 2015 / Victoria White

Moberg Pharma today announced that the European Patent Office has issued a Patent relating to its topical treatment MOB-015 for onychomycosis (nail fungus)…


Moberg Pharma announces issue of U.S. Patent for Kerasal Nail

Industry news / 25 March 2015 / Victoria White

Moberg Pharma have announced that the United States Patent and Trademark Office has issued a patent for Moberg Pharma’s market-leading product Kerasal Nail…

Moberg Pharma

Moberg Pharma AB (Publ) year-end report 2014

Industry news / 27 February 2015 / Moberg Pharma

Successful fourth quarter and the first profitable full year…

Moberg Pharma

Invitation – Presentation of Moberg Pharma’s fourth quarter and full year results 2014

Industry news / 18 February 2015 / Moberg Pharma

On February 27, at 08:00 CET, Moberg Pharma AB (OMX: MOB) will publish its report for the fourth quarter and full year 2014…

Moberg Pharma

Moberg Pharma launches innovative new Kerasal product in the U.S.

Industry news / 13 February 2015 / Moberg Pharma

Moberg Pharma AB announced that it shipped opening orders of its new line extension, Kerasal® Complete Care in Walgreens, the #1 drug chain in the U.S., with additional retailers expected to follow…

Moberg Pharma

Moberg Pharma extends distribution agreement with Menarini Group for Emtrix to Russia

Industry news / 9 February 2015 / Moberg Pharma

Moberg Pharma AB announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine…

Moberg Pharma

Moberg Pharma’s fungal nail product approved in China

Industry news / 27 January 2015 / Moberg Pharma

Moberg Pharma AB announced that its partner, Menarini Asia-Pacific, has received approval for Moberg’s fungal nail product in China…

Moberg Pharma

Moberg Pharma appoints Jeff Vernimb as US General Manager

Industry news / 20 November 2014 / Moberg Pharma

Moberg Pharma AB have appointed Jeff Vernimb as General Manager for its U.S. operations and a member of Moberg’s Management Team – effective from December 15, 2014…

Moberg Pharma

Moberg Pharma changes in Board of Directors

Industry news / 17 November 2014 / Moberg Pharma

Moberg Pharma AB announces that George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...